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RESEARCH REPORT

Tardive dyskinesia risk with ﬁrst- and second-generation
antipsychotics in comparative randomized controlled trials:
a meta-analysis
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1

Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA; 2Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine,
Hempstead, NY, USA; 3Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; 4Department of Psychiatry and Psychotherapy,
Klinikum rechts der Isar der Technischen Universität München, Munich, Germany; 5Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, and Department of Child and
Adolescent Psychiatry, Berlin Institute of Health, Berlin, Germany

Tardive dyskinesia (TD) risk with D2/serotonin receptor antagonists or D2 receptor partial agonists (second-generation antipsychotics, SGAs) is
considered signiﬁcantly lower than with D2 antagonists (ﬁrst-generation antipsychotics, FGAs). As some reports questioned this notion, we metaanalyzed randomized controlled studies (RCTs) to estimate the risk ratio (RR) and annualized rate ratio (RaR) of TD comparing SGAs vs. FGAs
and SGAs vs. SGAs. Additionally, we calculated raw and annualized pooled TD rates for each antipsychotic. Data from 57 head-to-head RCTs, including 32 FGA and 86 SGA arms, were meta-analyzed, yielding 32 FGA-SGA pairs and 35 SGA-SGA pairs. The annualized TD incidence across
FGA arms was 6.5% (95% CI: 5.3-7.8%) vs. 2.6% (95% CI: 2.0-3.1%) across SGA arms. TD risk and annualized rates were lower with SGAs
vs. FGAs (RR=0.47, 95% CI: 0.39-0.57, p<0.0001, k=28; RaR=0.35, 95% CI: 0.28-0.45, p<0.0001, number-needed-to-treat, NNT=20). Metaregression showed no FGA dose effect on FGA-SGA comparisons (Z=−1.03, p=0.30). FGA-SGA TD RaRs differed by SGA comparator (Q=21.8,
df=7, p=0.003), with a signiﬁcant advantage of olanzapine and aripiprazole over other non-clozapine SGAs in exploratory pairwise comparisons.
SGA-SGA comparisons conﬁrmed the olanzapine advantage vs. non-clozapine SGAs (RaR=0.66, 95% CI: 0.49-0.88, p=0.006, k=17, NNT=100).
This meta-analysis conﬁrms a clinically meaningfully lower TD risk with SGAs vs. FGAs, which is not driven by high dose FGA comparators, and
documents signiﬁcant differences with respect to this risk between individual SGAs.
Key words: Tardive dyskinesia, ﬁrst-generation antipsychotics, second-generation antipsychotics, randomized controlled studies, schizophrenia, meta-analysis, annualized incidence, clozapine, aripiprazole
(World Psychiatry 2018;17:330–340)

Can tardive dyskinesia (TD), a condition of potentially irreversible abnormal involuntary movements associated to treatment with D2 receptor antagonists (ﬁrst-generation antipsychotics, FGAs), and producing a signiﬁcant impairment of
functioning and quality of life1,2, be considered relatively irrelevant for treatment with second-generation antipsychotics (SGAs)?
Based on studies conducted until 2004, the annual TD incidence during SGA treatment was estimated as 0.8% in non-elderly adults3, one ﬁfth of the rate (5.4%) with FGAs. Surprisingly,
however, equal rates of TD during SGA or select FGA treatment
were reported in two large randomized controlled trials (RCTs)
in schizophrenia, the UK-based Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS-1)4 and the
US-based Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study5. As a pre-emptive risk reduction, the
CATIE study5 did not include subjects with a history of TD into
the FGA arms, but only in the SGA arms, limiting the interpretation of reported TD rates. Moreover, most meta-analyses of
SGA treatment do not comment on TD risk, as most RCTs are
shorter than 3 months (the minimum duration required to
diagnose TD6,7 and/or report continuous outcome measures
for dyskinesia), being not suited to identify TD cases8-10. Thus,
information on incident TD during RCTs is very scarce.
We recently summarized prevalence rates of TD11, ﬁnding
that 20% of subjects with current SGA treatment presented
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with at least mild screening-based probable TD. This observation contrasts with the clinical perception of vanishing TD during SGA treatment, possibly due to the overrating of mild TD
cases detected only with screening, but not perceived as clinically meaningful. Importantly, however, prevalence rates are
inappropriate indicators of treatment-associated risk for TD,
as the antipsychotic given at the time of TD development may
not be the one prescribed at the time of TD assessment.
To determine the incidence and the relative risk of treatment-emergent TD with FGA or SGA treatment, we searched
for RCTs with a duration of ≥3 months comparing ≥2 antipsychotics and reporting incident TD cases. We aimed to describe TD risk by: a) class-wise comparisons of pooled FGAs to
each speciﬁc SGA, b) drug-wise comparisons of a speciﬁc FGA
to one or more speciﬁc SGAs, and c) comparisons between individual SGAs.
Based on our earlier study3, we hypothesized that the incidence and the relative TD risk would be lower with SGAs vs.
FGAs. Moreover, based on the association between TD incidence and FGA dose12, we hypothesized that studies using
high dose FGA comparators would drive the estimated risk reduction of SGAs vs. FGAs. Lastly, based on the association between TD incidence and early parkinsonian side effects12, we
hypothesized that SGAs with a higher propensity for extrapyramidal side effects (EPS) would be associated to a higher risk
for TD vs. SGAs with lower EPS potential.
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METHODS
Literature search
Two authors (CC, MC) independently conducted a PubMed/
Web of Science search without language or time restriction for
comparative randomized antipsychotic studies (last search update: January 31, 2018). The following terms were used in the
advanced search option: all ﬁelds (= any ﬁeld): (antipsychotic*)
AND (amisulprid* OR aripiprazol* OR asenapin* OR clozapine
OR olanzapin* OR paliperidon* OR quetiapin* OR risperidon*
OR sertindole OR ziprasidon* OR zotepin* OR iloperidon* OR
cariprazin* OR brexpiprazol* OR lurasidone OR blonanserin
OR melperone) AND (randomized controlled trial); publication
type: NOT review.
Additionally, we hand-searched references from Cochrane
meta-analyses on SGAs. Whenever data needed for the metaanalysis were missing, we repeatedly contacted the authors for
additional information and for access to data repositories for
unpublished data.

Study inclusion criteria
We included all head-to-head comparisons of one of the
above listed antipsychotics in any (oral or i.m.) form of administration to any FGA or other SGA without restriction on age or
gender of participants. Requiring that at least one arm consisted of an SGA, we ensured that any FGA comparator was studied at the same time as SGAs were available, avoiding potential
biases due to time effects regarding different patient populations and dosing schemas in trials before availability of SGAs.
Included studies had to provide information on the rate of
probable treatment-emergent TD in subjects free of TD at
study baseline. The diagnosis of probable TD could be clinical
or scale-based, as long as diagnostic criteria were clearly deﬁned and identical for all treatment arms. Fixed and ﬂexible
dose studies were eligible, as long as baseline randomization
was present. Any psychiatric or medical diagnosis was allowed, except for movement disorders. Hence, antipsychotic
trials in schizophrenia patients with a serious concomitant
medical illness as an inclusion criterion were not excluded.
Studies allowing concomitant or prophylactic anticholinergic
medication were similarly included, and anticholinergic medication was assessed as moderator. Trials that allowed switching of treatments between groups were excluded. For trials
which had a crossover design, only results from the ﬁrst randomization period were considered, to avoid carry-over effects.
A minimum trial duration of three months was considered
for the identiﬁcation of cases of probable dyskinesia. However,
longer observation periods are more appropriate, and the duration of exposure was explored as moderator of TD incidence.
Trials in which treatment consisted of concomitant use of ≥2
antipsychotics per individual were excluded, as we aimed to
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differentiate effects of speciﬁc antipsychotics. We did not exclude randomized, open-label studies, but excluded these in
sensitivity analyses to address the lack of blinding, which has
been shown to be a substantial source of bias13.

Data extraction
Two authors (MC, CC) independently checked eligibility
and extracted data. Any disagreement was resolved by discussion/consensus.
In addition to antipsychotic-speciﬁc and class-wise TD rates,
we extracted: chlorpromazine equivalent dose for FGAs and
olanzapine equivalent dose for SGAs (using the methods described by Leucht et al14, where 300 mg of chlorpromazine
equals 10 mg of olanzapine according to the daily dose method), publication year, study design, geographic region, patient
gender, age, ethnicity, clinical diagnoses, illness duration, disease severity, comorbid parkinsonism, TD rating scale and
scores, diagnostic TD criteria. Data on TD severity were provided in a minority of studies only. Whenever possible, rates of
persistent TD were used, as this measure is clinically more
meaningful and less prone to variability than probable TD.

Statistical analysis
We conducted two parallel sets of pairwise, head-to-head
analyses: FGA-SGA across-class comparisons and SGA-SGA
within-class comparisons. In both sets of analyses, the effect
size calculation was based on the pairing of treatment arms as
in the original RCT to maintain control of confounding variables. Thus, we calculated an effect size for each available
head-to-head combination. From all studies we extracted the
number of TD cases per treatment arm (N = intent-to-treat,
ITT) and the duration of antipsychotic exposure within this
group. Then, we calculated the raw TD incidence risk, as the
ratio of TD cases per total exposed subject number, and the annualized TD incidence risk, as cases per exposed subject number per time of antipsychotic exposure (i.e., person years), each
with their respective 95% conﬁdence intervals (CIs). Numbersneeded-to-treat (NNTs) reﬂecting reduced annualized risk for
TD were calculated dividing 1 by the rate difference.
We next used subgroup comparisons and meta-regression
to explore the relative risk change by antipsychotic class and
for speciﬁc moderators: mean age, male gender percentage,
Caucasian ethnicity percentage, dosing (dichotomizing mean/
median study dose – i.e., <500 mg vs. ≥500 mg chlorpromazine
equivalent, and <3 mg vs. ≥3 mg haloperidol in studies using
haloperidol – or dichotomizing the maximum allowed haloperidol dose range: <10 mg vs. ≥10 mg), illness duration and
stage, disease severity, comorbid parkinsonism, information
on prior FGA exposure, publication year, study design, duration and sponsorship, data source, case deﬁnition, geographic
region.
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A multivariable analysis was performed, including signiﬁcant moderators which had been identiﬁed in univariate analysis. Since TD risk is cumulative and higher the longer patients are followed, we conducted these moderator analyses
only for annualized rate ratios (RaRs) that correct for any differences in observation time. All analyses used a random effects model and were two-sided, with alpha=0.05. Data were
analyzed with Comprehensive Meta-Analysis Version 3.

RESULTS
Search results
Of 3,438 hits in PubMed and Web of Science, 273 full-text
articles were screened, resulting in 57 articles that fulﬁlled all
inclusion criteria (Figure 1). Notably, a lack of TD reporting resulted in the exclusion of 75 studies of eligible cohorts.

Sample characteristics
FGA-SGA studies
Thirty-two randomized studies comparing FGAs to SGAs
and providing data on TD incidence in 10,706 subjects were included5,15-45. Twenty-two of them were double-blind studies5,15,17,19,21-25,27-29,31,33,36,38-44 and ten were randomized open
studies16,18,20,26,30,32,34,37,39,45 (partly with blinded ratings). Haloperidol was the FGA comparator in the majority of studies. All
but one study43 included subjects with schizophrenia-spec-

trum disorders, and one third of the studies were industry
independent5,22,23,25,28,30,34-36,39,42,45.
Overall, the studies included 65.6% males, 63.2% Caucasians, with a mean age of 37.712.4 years and a mean illness duration of 13.212.6 years. The mean chlorpromazine equivalent dose was 423.9252.4 mg/day (range: 69733.5 mg/day) for FGA treatment, and 522.6199.3 mg/day
(range: 118-905.7 mg/day) for SGA treatment14. The mean
PANSS total (from the ﬁfteen studies reporting this measure5,21-24,27-30,33,34,36,38,40,42) was 76.320.2 at baseline. The
median study duration (by design) was one year (interquartile range, IQR: 0.44-2.0). The median observed follow-up
lasted 108 person years (IQR: 34.5-254.3) for SGAs and 73.1
person years (IQR: 25.0-117.6) for FGAs.
Few studies included only subjects with ﬁrst-episode or
early-phase schizophrenia. The reported mean illness duration was 14 years (IQR: 10.6-17.1, k=21) for patients on SGAs
and 13.7 years (IQR: 10.2-17.4, k=21) for patients on FGAs.
Data on prior FGA exposure were very sparse; sixteen studies5,16,24,27,29,30,32,34-37,39,41,42,45,46 reported that included subjects had prior FGA exposure. The mean percentage of patients with pre-baseline FGA exposure was 76.430.5% (IQR:
40.0-100%, k=12).
The majority (81.3%) of FGA-SGA studies used standardized
screening instruments to detect and report dyskinesia. The Abnormal Involuntary Movement Scale (AIMS) was mostly used
in conjunction with Schooler-Kane criteria for probable TD.
Four studies5,21,23,32 reported both probable and persistent TD,
and ﬁve studies15,22,24,38,42 reported persistent TD only. Systematic screening was also performed using the Extrapyramidal Symptom Rating Scale (ESRS)19,23,24,41,47, the St. Hans Rat-

Potentially relevant articles (N=3,438)

Articles excluded at abstract level (N=3,165)

Full text articles retrieved for detailed evaluation (N=273)
Articles excluded (N=216)
• Non-randomized studies (N=12)
• ≤3 months duration (N=47)
• No TD data reported + no screening or clinical
assessment (N=20)
• No TD data reported despite systematic screening in
methods (N=32)
• No TD data reported + <6 months (N=23)
• Different study focus (N=18)
• Subgroup better reported elsewhere (N=44)
• No or negative reply from authors (N=20)
RCTs included in the meta-analysis (N=57; study arms=118)
Figure 1 PRISMA ﬂow chart. TD – tardive dyskinesia, RCTs – randomized controlled trials
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ing Scale30 and the Dyskinesia Rating Scale25. Only six studies
assessed TD based on clinical reporting16,17,26,28,39,45.

SGA-SGA studies
Twenty-three randomized studies comparing one SGA to
another SGA and providing data on TD incidence in 9,153
subjects were included in the analysis (comparators: olanzapine31,47-59, clozapine60-62, or risperidone63-68).
SGA-SGA comparisons also included treatment arms from
FGA-SGA studies with randomization into multiple SGA arms
and with TD data reporting by speciﬁc antipsychotic, thus
adding data on SGA treatment from ﬁve studies listed also
above5,30,31,34,41.
Based on the frequency of included studies and their use of
speciﬁc antipsychotics (but not a priori), the SGA-SGA studies
were grouped into the following three subsets for analyses: a)
19 comparisons with olanzapine as one comparator; b) three
comparisons with clozapine as one comparator; c) six comparisons with risperidone or paliperidone (which is metabolized from risperidone) as one comparator. This latter group
excluded olanzapine as the other comparator, as these headto-head comparisons had been included in the ﬁrst subset. We
used sensitivity analyses to separate the effect of risperidoneolanzapine head-to-head comparisons in the studies of the
ﬁrst and third group.
The majority of studies included adults with schizophrenia
spectrum disorders; two studies included subjects with bipolar
disorder57,64; two subjects with acute psychosis51,52; one patients with ﬁrst-episode psychosis48; and one patients with
pediatric schizophrenia or schizoaffective disorder22.
Overall, these studies included 62.2% males, 67.0% Caucasian, with a mean age of 37.010.7 years and a mean illness
duration of 11.86.8 years. Four studies included only subjects with ﬁrst-episode or early-phase schizophrenia22,30,48,51.
Data on prior FGA exposure were reported only in six studies
(being 0-33% in three studies30,47,51, and >50% in two5,50).
SGA doses converted into mean olanzapine equivalent
doses14 were: a) for studies with olanzapine, 13.53.4 mg/day
(range: 4.8-20.1 mg/day) for olanzapine and 10.62.9 mg/day
(range: 6.8-13.6 mg/day) for the comparators; b) for studies
with clozapine, 10.7 mg/day for clozapine and 21.04.6 mg/
day (range: 19.0-23.4 mg/day) for the comparators; c) for
studies with risperidone or paliperidone, 12.13.2 mg/day
(range: 8.6-16.0 mg/day) for risperidone/paliperidone and
12.32.7 mg/day (range: 8.6-15.0 mg/day) for the comparators. The mean PANSS total (from studies reporting this measure22,47-49,52-56,60-62,64-67) was 79.516.6 at baseline.
In contrast to FGA-SGA studies, the use of standardized TD
screening instruments was slightly lower in SGA-SGA studies
(64.3%), with a third of studies relying on clinical or patient reporting48,50,52,54,58,63,67,68. The majority of studies reported
probable TD, except for CATIE5.
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Full sample analyses: mean TD incidence in randomized
studies
The estimated weighted mean incidence of TD across all
FGA treatment groups was 6.5% (95% CI: 4.6-9.0%) for 3,763
subjects in 32 treatment arms. Similarly, the annualized incidence was 6.5% (95% CI: 5.3-7.8%; see Table 1 for speciﬁc FGAs).
The estimated weighted mean incidence of TD across all
SGA treatment groups was 3.0% (95% CI: 2.4-3.8%) for 15,092
subjects in 86 treatment arms. The annualized incidence was
2.6% (95% CI: 2.0-3.1%; see Table 1 for speciﬁc SGAs).
As randomization with regard to TD was unbalanced in the
CATIE study (subjects with a history of TD were barred from
randomization to FGA treatment), a sensitivity analysis was
performed after excluding the CATIE data, yielding a weighted
mean annualized incidence of TD for FGAs of 6.8% (95% CI:
5.5-8.1%) and for SGAs of 2.6% (95% CI: 2.1-3.2%).
Further sensitivity analyses corroborated the range of observations above, but also showed slightly lower rates for SGAs
after exclusion of clozapine studies (weighted mean annualized incidence of 2.4%, 95% CI: 1.9-3.0).
TD incidence in studies using only clinical reporting (but
not systematic screening) was 3.8% (95% CI: 2.1-6.7%) for FGA
arms, and 0.9% (95% CI: 0.3-2.4%) for SGA arms.

FGA-SGA sample analyses: TD risk and moderators of TD
risk differences
Of the 32 FGA-SGA included studies, only 28 contributed
analytically to the comparative TD risk analysis, as meta-analytic risk calculations exclude studies with zero events in both
treatment arms.

Primary analysis
The estimated TD risk ratio (RR) was signiﬁcantly lower with
SGAs relative to FGAs (RR=0.47, 95% CI: 0.39-0.57, p<0.0001,
k=28). Similarly, the estimated TD RaR, reﬂecting the annualized incidence, was signiﬁcantly lower in SGAs relative to FGAs
(RaR=0.35, 95% CI: 0.28-0.45, p<0.0001, k=28; NNT=20, 95% CI:
15-31) (Figure 2).
The estimated TD RR after exclusion of CATIE data was 0.35
(95% CI: 0.27-0.44, p<0.0001, k=27). The TD RaR after CATIE
exclusion was 0.34 (95% CI: 0.27-0.44, p<0.0001, k=27).

Moderator analyses of TD RaRs
The mean TD RaR varied signiﬁcantly by SGA comparator
(Q=21.8, df=7, p=0.003). The advantage of SGAs vs. FGAs was
most prominent with aripiprazole and smallest with quetiapine (Table 2). Exploratory pairwise comparisons showed signiﬁcantly lower RaRs with aripiprazole relative to all other
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Table 1 Incidence of tardive dyskinesia (TD) for specific antipsychotics
Mean raw TD incidence
Antipsychotic

Mean annualized TD incidence

N. studies/treatment arms

N. subjects

%

95% CI

%

1

853

3.3

0.5-17.4

3.7

95% CI

FGAs
Perphenazine

0.1-6.7
–0.8 to 16.5

Molindone

1

20

2.4

0.1-38.5

4.2

Haloperidol

22

2,975

6.6

4.5-9.6

7.5

Chlorpromazine

1

80

21.3

4.4-60.1

11.2

4.8-17.7

Fluphenazine

1

28

3.6

3.0-32.8

12.5

12.3-37.3

Aripiprazole

3

1,215

0.9

0.3-3.1

1.7

–0.8 to 4.1

Amisulpride

3

558

1.5

0.4-5.4

2.4

–0.4 to 5.2

Asenapine

4

1,472

1.2

0.5-3.3

2.4

–0.1 to 4.8

5.9-9.2

SGAs

Risperidone

20

853

4.2

2.6-6.6

2.4

1.2-3.5

Quetiapine

6

221

2.8

0.2-1.1

2.5

0.2-4.8

Olanzapine

29

5,686

2.7

1.9-4.0

2.9

1.8-3.9

Ziprasidone

7

918

3.5

1.6-7.5

3.5

1.3-5.7

Clozapine

6

348

8.2

3.9-16.6

4.2

1.7-6.7

Lurasidone

1

427

2.6

0.5-13.1

4.8

–0.2 to 9.3

The TD rates for the individual medications are not directly comparable, as they do not originate from randomized trials in which those medications were compared
head-to-head, but are pooled irrespective of study comparators. FGAs – first-generation antipsychotics, SGAs – second-generation antipsychotics

SGAs. Moreover, RaRs with olanzapine were also signiﬁcantly
lower relative to risperidone and quetiapine (Table 3).
The mean TD RaR did not vary signiﬁcantly by FGA comparator (Q=0.23, df=1, p=0.63). The advantage of SGAs over
FGAs persisted after exclusion of all studies in which haloperidol was used as the FGA comparator (RaR=0.39, 95% CI: 0.250.61, p<0.0001, k=8). In those studies with haloperidol as the
comparator, similar RaRs were obtained (RaR=0.34, 95% CI:
0.26-0.45, p<0.0001, k=20). In the studies with speciﬁed, nonhaloperidol FGAs5,21,25,34, a somewhat weaker, but still signiﬁcant advantage of SGAs over FGAs emerged (RaR=0.47, 95% CI:
0.27-0.82, p=0.007, k=4). The comparison with all other studies
(i.e., those that included haloperidol as the only, or as one possible FGA) was non-signiﬁcant (Q=1.27, df=1, p=0.26).
TD RaRs were similar in ﬁrst episode/early-phase psychosis cohorts22-25,27,30 vs. the remaining unrestricted cohorts
(Q=0.04, df=1, p=0.85). Prior FGA exposure was not consistently reported, and no cohort explicitly included only subjects
without prior FGA exposure.
TD RaRs varied signiﬁcantly by sponsorship (Q=10.0, df=1,
p=0.003). The reduction in TD incidence associated with SGA
treatment was accentuated in industry-sponsored relative to
academic studies, but persisted independently in both of them
(academic studies: RaR=0.59, 95% CI: 0.39-0.87, p=0.008, k=11;
industry-sponsored studies: RaR=0.28, 95% CI: 0.21-0.35, p<
0.001, k=20).
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A mixed regression model including SGA comparator and
sponsorship (Q=20.74, df=6, p=0.002) conﬁrmed the independent effect of SGA comparator (Q=10.78, df=5, p=0.05),
while no signiﬁcant effect of sponsorship was found (Z=−1.2,
df=1, p=0.23).
Moderator and meta-regression analyses were non-signiﬁcant for age, gender, illness duration (both as years of disease
duration and categorically as ﬁrst episode/early-phase psychosis vs. other cohorts), disease severity, study region, study
duration, anticholinergic use, study design (open-label extension vs. blinded trial), year of study start, and case deﬁnition.
There was no effect of FGA dose on TD rate ratios, neither
when data were dichotomized (below vs. above 500 mg chlorpromazine equivalents, Q=0.19, df=1, p=0.66), nor when mean
FGA dose in chlorpromazine equivalents was used in a metaregression model (Z=−1.03, p=0.30). Similarly, there was no effect of the FGA-SGA ratio on TD RaRs (Z=1.56; p=0.12).
Data on TD severity were provided in a minority of studies
(31.3%). TD severity was described in very heterogeneous
formats, which did not allow for the use of this variable in the
meta-analysis. Discontinuation due to TD was reported rarely,
but slightly more frequently in FGAs (N=1 in FGA vs. N=0 in
SGA21; 2.7% in FGA vs. 0.7% with paliperidone36). Greater
severity of TD with FGAs was reported repeatedly5,23,32,35,38.
Reports of severe cases were rare in general, and found only in
FGA-treated subjects in four studies27,38,40,41.
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Figure 2 Forest plot of tardive dyskinesia rate ratios of randomized studies comparing ﬁrst-generation antipsychotics (FGAs) to second generation antipsychotics (SGAs). ARI – aripiprazole, AMI – amisulpride, CLZ – clozapine, CPZ – chlorpromazine, HAL – haloperidol, OLZ – olanzapine, PALI – paliperidone, PER – perphenazine, RIS – risperidone, ZIP – ziprasidone

SGA-SGA sample analyses: TD risk and moderators of TD
RaR differences
Olanzapine vs. all other non-clozapine SGAs
Of the 28 SGA-SGA included studies, the most frequently
studied SGA was olanzapine, which was a SGA comparator in
17 studies against other non-clozapine SGAs. As CATIE5 and

Table 2 Mean annualized tardive dyskinesia (TD) rate ratios in SGAs
vs. FGAs
SGA

N. treatment
arms

N. subjects

Mean TD rate ratio
vs. FGA (95% CI)

p

Amisulpride

3

558

0.37 (0.15-0.91)

0.032

Aripiprazole

1

1,215

0.045 (0.01-0.19)

0.000

Clozapine

2

405

0.39 (0.22-0.70)

0.001

Olanzapine

12

5,624

0.25 (0.19-0.34)

0.000

Paliperidone

1

145

0.70 (0.35-1.36)

0.294

Quetiapine

2

786

0.94 (0.35-0.91)

0.915

Risperidone

8

2,479

0.38 (0.25-0.58)

0.000

Ziprasidone

4

887

0.57 (0.26-1.27)

0.169

FGAs – first-generation antipsychotics, SGAs – second-generation antipsychotics
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EUFEST30 randomized patients also to SGA treatment arms,
19 comparative olanzapine/non-clozapine SGA studies were
available. In these 19 studies, comparators were risperidone
(k=9), asenapine (k=5), quetiapine (k=4), ziprasidone (k=3),
amisulpiride (k=1) and aripiprazole (k=1). The mean dose in
the olanzapine treatment arms was 13.53.4 mg/day, being
10.62.9 mg/day in the comparators, recalculated via mean
olanzapine equivalent for all14. Three studies22,52,68 reported no
cases of TD in all arms and did thus not contribute to risk calculations, as the risk of non-occurrence is formally inestimable.
The estimated TD risk ratio was signiﬁcantly lower with
olanzapine relative to other non-clozapine SGAs (RR=0.67,
95% CI: 0.50-0.90, p=0.008, k=17; NNT=100, 95% CI: 63-250).
Similarly, the estimated TD RaR was signiﬁcantly lower with
olanzapine relative to non-clozapine SGAs (RaR=0.66, 95% CI:
0.49-0.88, p=0.006, k=17).
Moderator analyses of TD RaRs were non-signiﬁcant, including age, gender, study region, olanzapine equivalent dose, anticholinergic use, percentage of subjects with prior FGA exposure, year of study start, illness duration, illness stage (ﬁrst-episode yes/no), sponsorship, and comparator SGA study design.
Treatment-related TD RaRs were signiﬁcantly lower with
olanzapine relative to risperidone (RaR=0.57, 95% CI: 0.370.89, p=0.015, k=6), which represented the largest comparator
subgroup. No other differences were found for the other SGAs
when analyzed in exploratory pairwise comparisons.
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Table 3 Moderating effects of the comparator SGA on annualized rate ratios of treatment emergent tardive dyskinesia in studies comparing FGAs
vs. SGAs
SGA comparator in
FGA study

Amisulpride

Clozapine

Olanzapine

Quetiapine

Aripiprazole

Q=5.75, p=0.017

Q=7.14, p=0.008

Q=5.04, p=0.025

Q=4.24, p=0.039

Q=11.27, p=0.004

Q=8.84, p=0.003

Amisulpride

-

Q=0.07, p=0.94

Q=0.65, p=0.42

Q=1.84, p=0.17

Q=2.84, p=0.28

Q=0.49, p=0.49

Q=1.72, p=0.19

Q=2.72, p=0.13

Q=2.52, p=0.28

Q=0.58, p=0.45

Q=6.12, p=0.013

Q=8.5, p=0.015

Q=3.6, p=0.06

-

Q=4.15, p=0.15

Q=0.608, p=0.43

Clozapine

-

Olanzapine

-

Quetiapine

Risperidone

Risperidone

-

Ziprasidone

Q=2.58, p=0.27

Significant effects are highlighted in bold prints. FGAs – first-generation antipsychotics, SGAs – second-generation antipsychotics

To address the possibility that the head-to-head studies
comparing olanzapine vs. risperidone were driving the favorable TD RaRs of olanzapine vs. non-clozapine SGAs, we excluded those studies in a sensitivity analysis. The TD RaR remained signiﬁcantly lower with olanzapine relative to all other
non-clozapine and non-risperidone SGAs (RaR=0.68, 95% CI:
0.46-0.99, p=0.047, k=12).

Clozapine vs. non-clozapine SGAs
There were only three studies comparing clozapine against
another SGA, with two of them vs. olanzapine61,62, and one vs.
mixed SGAs60, where olanzapine was used in 50% of subjects.
These studies included only subjects with a schizophrenia
spectrum disorder diagnosis. Subjects were 71% male, 77%
Caucasian, with a mean age of 38.71.1 years, a mean illness
duration of 17.35.1 years, and mean doses of 318.017.1 mg/
day for clozapine and 21.02.2 mg/day for olanzapine.
There was no difference regarding probable treatment-emergent TD between clozapine and non-clozapine SGAs (RR=1.07,
95% CI: 0.49-2.34, p=0.86, k=3; RaR=1.10, 95% CI: 0.66-1.90,
p=0.71, k=3).

Risperidone/paliperidone vs. non-olanzapine SGAs
There were six studies comparing risperidone or paliperidone against a different non-olanzapine/non-clozapine SGA,
four of which used long-acting injectables (LAIs) (risperidoneLAI = 3, paliperidone-LAI = 1), and additional treatment arms
from CATIE were also included in this subgroup comparison.
The comparators were aripiprazole (k=2), lurasidone (k=1),
quetiapine (k=1), ziprasidone (k=1) and mixed SGAs (k=1).
Five of the studies included subjects with a schizophrenia
spectrum disorder diagnosis, and one was performed in bipolar disorder patients64. Subjects were 56% male, 51% Caucasian, with a mean age of 36.85.7 years, and a mean illness
duration of 10.93.3 years.
There was no difference in RRs or RaRs of probable treat-
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ment-emergent TD between risperidone/paliperidone treatment arms and SGA comparators (RR=0.88; 95% CI: 0.50-1.56,
p=0.66, k=7; RaR=0.94, 95% CI: 0.65-1.35, p=0.72, k=7).
To address the inﬂuence of risperidone-olanzapine headto-head comparisons that were grouped primarily into the
ﬁrst analysis, we added these studies in a sensitivity analysis
to the third set analyses. Doing so, there was no difference in
RaRs for probable treatment-emergent TD between risperidone/paliperidone treatment arms and all other SGA comparators including olanzapine (RaR=1.24, 95% CI: 0.91-1.60,
p=0.20, k=12).

DISCUSSION
Class-wise TD risk
This meta-analysis on treatment-emergent TD during comparative randomized controlled trials shows an overall low, but
still clinically relevant incidence of TD (annualized incidence:
FGAs=6.5%; SGAs=2.6%). However, these rates are based only
on probable and not persistent TD and may be inﬂated due to
rating scale based assessments that do not take into consideration severity or impact. Conversely, the raw TD incidence
rates based on clinical observation (FGAs=3.8%, SGAs=0.9%)
have clinical face validity, but may be underestimates.
We conﬁrmed our hypothesis of lower incidence rates of
TD during SGA vs. FGA treatment, with a relative risk and annualized rate reduction to one third of the FGA rate and a
NNT=20. Interestingly, the rate of clinically reported, but not
screening-based TD, which may reﬂect the more severe and
clinically relevant cases, matches earlier incidence reports of
TD risk during clinical FGA use and during early clinical trials
with SGA treatment3.
The signiﬁcant TD risk reduction with SGAs found in this
meta-analysis contrasts to the ﬁndings of the UK-based CUtLASS-1 study4 and the US-based CATIE study5, which both
conveyed the impression that the TD risk of FGAs and SGAs did
not differ. While our dataset consisted predominantly of studies that used haloperidol as the FGA comparator, our analyses
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exploring the role of haloperidol as the comparator showed
that it did not drive the FGA-SGA class difference. TD RaRs in
studies with haloperidol as the FGA comparator did not differ
from those that used pooled groups of mixed FGAs (including
CATIE and CUtLASS); and both subgroups of FGA comparators
were independently associated with signiﬁcantly greater TD
risk than the respective SGA comparators.
Notably, CATIE and CUtLASS had methodological limitations regarding the speciﬁc question of EPS, as they were designed to assess antipsychotic efﬁcacy. Contrasting to the remaining body of studies included in this meta-analysis, the
FGA arms of the CATIE study5 did not include subjects with a
history of TD, as these subjects are at increased risk of TD
upon re-exposure to FGAs. Similarly, contrasting to the remaining body of studies included in this meta-analysis, the
FGA arm of the CUtLASS-1 study4 was dominated by the use
of sulpiride (58% of the FGA group). This antipsychotic has
been categorized as atypical based on its high dissociation
constant at the D2 receptor69, consistent with its exceptionally
low EPS risk70. Interestingly, our results are close to the ﬁndings of earlier large incidence studies in clinical cohorts that
demonstrated a signiﬁcant risk reduction for SGAs vs. FGAs of
0.5171 and of 0.55 after adjustment for lifetime antipsychotic
exposure72.
Due to the relatively low absolute annual risk of TD even
during FGA treatment, the NNT to achieve a risk reduction for
TD of 20 may appear too high to warrant an inﬂuence on clinical antipsychotic choice. On the other hand, the annual risk
underestimates the individual lifetime risk in chronic mental
illness, where antipsychotic exposure times range around six
years in 40 year olds72, being closer to 15 years in people with
schizophrenia spectrum disorders5. As the individual risk to
develop TD is cumulative, at least during the ﬁrst ﬁve years,
the risk reduction should also be seen as a cumulative gain
throughout the expected treatment period in each individual.
Contrary to earlier suggestions, the advantage of SGAs over
FGAs was not driven by high dose FGA studies, as dose was excluded as a systematic confound of the FGA-SGA risk comparisons. The potential dose effect was consistently ruled out via
different approaches: a) mean/median study dose; b) <500 mg
vs. ≥500 mg chlorpromazine equivalent and <3 mg vs. ≥3 mg
haloperidol; and c) <10 mg vs. ≥10 mg haloperidol. Importantly, this ﬁnding does contradict the repeated observation that
the individual risk for TD increases with higher FGA doses and
clinically relevant EPS12. Other risk factors, which are established for individual TD risk, such as age and gender, also had
no inﬂuence on the comparison of TD risks by antipsychotic
class, suggesting that antipsychotic dose, age and gender generalize as risk factors across different antipsychotics.
Consistent with our hypothesis, however, moderator analyses showed that TD risk reduction with SGAs differed with
speciﬁc SGA comparator. The relative risk reduction in comparisons vs. FGAs was most pronounced in studies with aripiprazole or olanzapine as SGA comparator. However, this information has to be interpreted cautiously, as TD RRs and RaRs
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vs. FGAs were accentuated in industry-sponsored studies. The
majority of olanzapine studies was industry sponsored and, although the mixed regression model formally conﬁrmed the
independent effect of SGA comparator, while no effect of sponsorship was found, no deﬁnite statement on this interaction
can be made due to the effect of factor collinearity between
olanzapine treatment and industry sponsorship.
Conversely, why would industry-sponsored trials with predominantly blinded ratings provide more favourable TD rates
for SGAs? The industry-sponsored studies differed regarding
the following factors: a) a higher number of subjects in FGA
treatment arms (but the number of subjects per treatment arm
is controlled by weighting in meta-analyses); b) higher dose
FGA comparator studies; c) higher mean age; d) fewer early
psychosis cohorts; and e) more clinical reporting-based TD assessment, which likely disfavours treatments with more severe
TD expression, such as FGAs. Nevertheless, none of these
factors was a signiﬁcant moderator of RaRs in this meta-analysis.

Within-SGA class comparisons
Consistent with the TD risk reduction of olanzapine and aripiprazole relative to FGAs, SGA-SGA comparisons seemed to
conﬁrm that agents with the lowest acute EPS risk73, i.e., clozapine and olanzapine, also have the lowest TD risk. However,
TD rate differences within the SGA class, based on an NNT of
100 for olanzapine vs. other non-clozapine SGAs, were rather
subtle, and quetiapine – that meta-analytically has very similar
acute EPS risk to olanzapine and aripiprazole73 – had the highest individual TD risk among SGA comparator trials.
Contrasting to the FGA-SGA comparisons, no effect of study
sponsor was present in the SGA-SGA analyses. However, most
of these studies were industry-sponsored, thus reducing the
ability to assess the impact of this factor. Nevertheless, the
NNT of 100 for the advantage of olanzapine underscores the
need to consider other adverse effects, particularly cardiometabolic risk, when making SGA choices.
Interestingly, and consistent with an earlier clinical TD incidence study72, the TD risk of clozapine and olanzapine was
similar in the three relevant studies. However, clozapine was
relatively under-dosed in those studies. Furthermore, there
were no studies of clozapine vs. non-olanzapine SGAs, a shortcoming that is all the more unfortunate, as olanzapine and clozapine share the major disadvantage of very signiﬁcant weight
gain. Since aripiprazole also seemed to have a particularly
lower TD risk vs. FGAs, comparing a D2 partial agonist to clozapine for TD risk would be valuable.
In contrast to our initial hypothesis that SGAs with higher
EPS potential, such as risperidone, would also have a higher TD risk, there were no notable differences of TD risks between non-olanzapine, non-clozapine SGAs, including risperidone/paliperidone in particular, but analyzable data were limited.
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Limitations
Multiple limitations have to be taken into consideration when
interpreting these results.
First, despite attempts to access this information, 75 randomized studies with an appropriate duration to provide information on TD risk could not be included in the analysis, as
they did not provide any information on TD (and we were unable to obtain such information from the authors). This number of studies signiﬁes a tremendous loss of information. Importantly, 32 of these studies reported on systematic screening
in their methods, but did not provide information on TD cases.
Instead, reporting of continuous sum scores of various dyskinesia-rating scales is common, but not informative, as has been
discussed before10,11.
Second, meta-analyses cannot estimate the risk of non-occurrence. Thus, studies that did not observe any cases of TD in
either arm did not contribute to risk calculations. They contribute to RARs though, thus their effect is reﬂected in the
NNTs. On the one hand, this is an unfortunate shortcoming of
the methodology; on the other hand, the data quality of large
studies in adults with chronic mental illness without a single
case of probable incident TD may also be questionable. Altogether, ﬁve studies including four treatment arm pairs for
FGA-SGA comparisons22,26,28,45 and two treatment arm pairs
for SGA-SGA comparisons22,52 did not contribute to the metaanalytic risk estimates. Subsequently, the estimated raw TD
rate is likely slightly lower under controlled study conditions,
and similarly the observed differences may also be minimally
lower.
Third, as the minimal exposure duration before TD can be
diagnosed is >3 months6,7, this time frame was chosen during
title/abstract screening for eligible studies. However, within
the time bin of studies lasting <6 months, only one (4-month)
study formally reported treatment-emergent dyskinesia. We,
thus, refrained from systematically requesting data on TD
from studies lasting <6 months (unless a formal screening for
dyskinesia was part of the study design). For all studies lasting
≥6 months, data were requested (even if the study design did
not include formal TD screening). It is often argued that shorter observation periods are contaminated by high rates of withdrawal dyskinesia. While this argument can only be tested on
a case-by-case evaluation of emerging dyskinesia cases, the
observation of signiﬁcantly increasing hyperkinesias during
the early treatment phase with haloperidol, but not with risperidone74, argues against this notion. The median study duration was one year, but longer observation periods would be
desirable.
Fourth, most studies reported probable mild TD, likely providing an overestimate of clinically relevant cases. While this is
a cautious, safety-oriented and well-recognized strategy, it
would be important to learn about the rates of persistent TD
along with scale-based severity measures. On the other, conservative end of the sensitivity spectrum, some studies, and in-
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creasingly more in SGA-SGA comparator trials, only provide
rates of clinically reported TD cases, not relying on rating scale
information. Our moderator analysis did not identify a systematic inﬂuence of screening techniques on RRs or RaRs, but differences in primary data acquisition need to be considered
when interpreting the results.
Fifth, the prevalence of TD in FGA-naïve cohorts treated
with SGAs has been reported to be lower than in subjects with
a history of FGA exposure11. There was, however, not a single
head-to-head RCT to test the effect of prior FGA exposure on
TD rates in the FGA-SGA comparison, and relatively sparse information on this issues in the SGA-SGA comparisons.
Sixth, as the absolute TD risk gets lower (in SGA studies in
general, relative to all FGA studies), the inﬂuence of potential
co-factors, such as co-treatment with other potentially TDcausing medications (e.g., metoclopramide75,76, ﬂunarizine77,
or antidepressants78) may represent a confound that has not
been addressed in the primary sources.
EPS have been characterized as the most important factor
predicting non-adherence during FGA treatment79. By contrast, akathisia, parkinsonism and dyskinesia failed to predict
adherence during the EUFEST and CATIE studies80, but predicted adherence in another large study including more than
2,000 patients treated with SGAs or FGAs81. Considering the
high incidence of clinically meaningful weight gain during
SGA treatment82, EPS partly lost their weight in clinical decision-making. Nevertheless, TD remains a clinical problem in
movement disorders clinics: SGA-related tardive syndromes
lately outnumbered FGA-related TD cases in a movement disorders clinic83, likely due to increasing on-label, as well as offlabel use of SGAs.

CONCLUSIONS
In conclusion, the historic notion of an SGA advantage with
regard to TD risk, which had been challenged by CATIE and
CUtLASS, has been conﬁrmed.
Importantly, the quality of data acquisition and reporting of
TD needs to return to earlier standards in future comparative
studies to understand whether or not SGAs differ among one
another with regard to TD risk. Risk estimates should span incidence, severity and persistence as well as impact on functioning and quality of life. Ideally, patient-level data repositories should help to accurately estimate rare side effects in antipsychotic studies.
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